Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice.
The chemokine receptors CCR2 and CCR5 play important roles in the recruitment of monocytes/macrophages and T cells. To better understand the role of both receptors in murine models of inflammatory diseases and to recognize potential problems when correlating these data to humans, we have generated mAbs against murine CCR2 and CCR5. In mice CCR2 is homogeneously expressed on monocytes and on 2--15% of T cells, closely resembling the expression pattern in humans. In contrast to humans, murine NK cells are highly CCR5 positive. In addition, CCR5 is expressed on 3--10% of CD4 and 10--40% of CD8-positive T cells and is weakly detectable on monocytes. Using a model of immune complex nephritis, we examined the effects of inflammation on chemokine receptor expression and found a 10-fold enrichment of CCR5(+) and CCR2(+) T cells in the inflamed kidneys. The activity of various chemokines and the antagonistic properties of the mAbs were measured by ligand-induced internalization of CCR2 and CCR5 on primary leukocytes. The Ab MC-21 (anti-CCR2) reduced the activity of murine monocyte chemotactic protein 1 by 95%, whereas the Ab MC-68 (anti-CCR5) blocked over 99% of the macrophage-inflammatory protein 1alpha and RANTES activity. MC-21 and MC-68 efficiently blocked the ligand binding to CCR2 and CCR5 with an IC(50) of 0.09 and 0.6--1.0 microg/ml, respectively. In good correlation to these in vitro data, MC-21 almost completely prevented the influx of monocytes in thioglycollate-induced peritonitis. Therefore, both Abs appear as useful reagents to further study the role of CCR2 and CCR5 in murine disease models.
Medical Policlinic, University of Munich, Munich, Germany. mack@medpoli.med.uni-muenchen.de
M
M
Mack
J
J
Cihak
C
C
Simonis
B
B
Luckow
A E
AE
Proudfoot
J
J
Plachý
H
H
Brühl
M
M
Frink
H J
HJ
Anders
V
V
Vielhauer
J
J
Pfirstinger
M
M
Stangassinger
D
D
Schlöndorff
D000818:Animals; D019138:Antibodies, Blocking / Q000378:metabolism / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000378:metabolism; D000918:Antibody Specificity; D001052:Apoferritins / Q000633:toxicity; D001667:Binding, Competitive / Q000276:immunology; D065100:CCR5 Receptor Antagonists; D016466:CHO Cells; D006224:Cricetinae; D015536:Down-Regulation / Q000276:immunology; D005921:Glomerulonephritis / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control; D007274:Injections, Intraperitoneal; D007962:Leukocytes / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010538:Peritonitis / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D054390:Receptors, CCR2; D019713:Receptors, CCR5 / Q000096:biosynthesis* / Q000276:immunology* / Q000378:metabolism; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000276:immunology* / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D013864:Thioglycolates / Q000633:toxicity
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D065100:CCR5 Receptor Antagonists; C515335:Ccr2 protein, mouse; C515336:Ccr2 protein, rat; D054390:Receptors, CCR2; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; D013864:Thioglycolates; D001052:Apoferritins